Compare FNWD & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | FNWD | HURA |
|---|---|---|
| Founded | 1994 | 2009 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Savings Institutions | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.2M | 144.3M |
| IPO Year | 1996 | N/A |
| Metric | FNWD | HURA |
|---|---|---|
| Price | $33.39 | $2.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $37.50 | $10.00 |
| AVG Volume (30 Days) | 2.8K | ★ 1.2M |
| Earning Date | 04-24-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.48% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.88 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.40 | N/A |
| Revenue Next Year | $5.44 | N/A |
| P/E Ratio | $17.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.46 | $0.41 |
| 52 Week High | $39.99 | $4.30 |
| Indicator | FNWD | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 37.77 | 62.35 |
| Support Level | $31.52 | $2.29 |
| Resistance Level | $38.79 | $2.74 |
| Average True Range (ATR) | 0.75 | 0.34 |
| MACD | -0.17 | 0.05 |
| Stochastic Oscillator | 52.17 | 65.51 |
Finward Bancorp is a bank holding company, which engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Saving Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out through the United States.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.